Gennao Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$15M
- Investors
-
5
Gennao General Information
Description
Developer of targeted nucleic acid therapeutics intended to cure muscle diseases. The company uses gene monoclonal antibody (GMAB) platform technology, which utilizes a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells, enabling the medical community and patients to optimize outcomes related to rare monogenic skeletal muscle diseases.
Contact Information
Website
www.gennao.comCorporate Office
- 311 Pennington Rocky Hill Road
- Building Number 21, Hopewell
- Pennington, NJ 08534
- United States
Corporate Office
- 311 Pennington Rocky Hill Road
- Building Number 21, Hopewell
- Pennington, NJ 08534
- United States
Gennao Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 08-Dec-2022 | $15M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 17-Dec-2021 | Completed | Startup |
Gennao Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Gennao Patents
Gennao Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025213130-A1 | Antibody drug conjugates | Pending | 04-Apr-2024 | ||
| WO-2025049905-A1 | Dnase co-expression in host cells | Inactive | 01-Sep-2023 | ||
| WO-2024197302-A1 | Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping | Inactive | 23-Mar-2023 | ||
| WO-2024158824-A1 | Antibody oligonucleotide conjugates | Inactive | 23-Jan-2023 | ||
| WO-2024145398-A1 | Antibody drug conjugates | Inactive | 27-Dec-2022 | A61K47/6843 |
Gennao Signals
Gennao Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| GordonMD Global Investments | PE/Buyout | Minority | ||
| CureDuchenne Ventures | Corporate Venture Capital | Minority | ||
| Logos Capital | Hedge Fund | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| Surveyor Capital | Hedge Fund | Minority |
Gennao FAQs
-
When was Gennao founded?
Gennao was founded in 2020.
-
Where is Gennao headquartered?
Gennao is headquartered in Pennington, NJ.
-
What is the size of Gennao?
Gennao has 11 total employees.
-
What industry is Gennao in?
Gennao’s primary industry is Biotechnology.
-
Is Gennao a private or public company?
Gennao is a Private company.
-
What is the current valuation of Gennao?
The current valuation of Gennao is .
-
What is Gennao’s current revenue?
The current revenue for Gennao is .
-
How much funding has Gennao raised over time?
Gennao has raised $55M.
-
Who are Gennao’s investors?
GordonMD Global Investments, CureDuchenne Ventures, Logos Capital, OrbiMed, and Surveyor Capital have invested in Gennao.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process